

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

Status: Recruiting

Eligibility Criteria

Age: Not specified

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- at least 12 years of age - for people with Alport Syndrome: confirmed diagnosis by genetic testing and /or kidney biopsy - for primary Focal Segmental Glomerulosclerosis (FSGS), (without any identifiable cause, and where the FSGS is confirmed by renal biopsy) or FSGS where there is documentation of a genetic mutation in a podocyte protein - female patients, as well as, female partners of male patients who are of child-bearing potential must be willing to not become pregnant for the complete duration of the study (90 days after the last dose of study medication) - males (including sterilized subjects) whose female partners have child-bearing potential, must agree to use male contraception (condoms) during the period from the time of signing the informed consent form (ICF) through 90 days after the last dose of study drug - contact study staff for additional criteria

Exclusion Criteria:

- uncontrolled diabetes mellitus as evidenced by an HbA1c greater or equal to 11% - uncontrolled high blood pressure - moderate or severe liver impairment - BMI greater than 40 - women who are pregnant or breast feeding - additional exclusion criteria apply (study staff will review)

Conditions & Interventions

Conditions:

Kidney, Prostate & Urinary

Keywords:

Clinics and Surgery Center (CSC), Alport Syndrome, Focal Segmental Glomerulosclerosis

More Information

Description: The main purpose of this study is to check how safe the study drug is and how well your body handles taking it. The study will also check: • if the study drug works to improve your kidney function • whether the study drug has an impact on your daily life • the amount of the study drug in your blood over a period of time (called pharmacokinetics)

Contact(s): Amy Hanson - amhanson@umn.edu

Principal Investigator: Michelle Rheault

IRB

Number: STUDY00015869

System ID: 38084

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.